semaj83/ctmatch_classification huggingface dataset:
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Symptomatic Dominant Liver Cyst All patients who are diagnosed with a dominant liver cyst with an indication for aspiration and sclerotherapy are suitable for in this study In order to be eligible to participate in this study, a subject must meet all of the following Age 18 years Indication for aspiration and sclerotherapy Providing informed consent  A potential subject who meets any of the following will be excluded from participation in this study Signs of cyst bleeding on ultrasound Signs of cyst infection (elevated CRP and/or leukocytes or temperature exceeding 38 degrees with the of a different focus) Cyst < 5 cm Coagulopathy (INR > 2 or platelets < 80 x 10^9) Severe co-morbidity contraindicating anesthesia (i.e. ASA 4 classification) Patients with a known hypersensitivity to SST analogues or any component of the pasireotide LAR or SQ formulations Pregnant or nursing women Symptomatic cholecystolithiasis QT interval related
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Gastroesophageal-junction Cancer patients with biopsy verified GEJ-cancer referred to the department of surgical gastroenterology, Rigshospitalet, which is considered resectable at MDT-conference >18 years old informed consent  < 18 years old Not informed consent
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 21.0-80.0,  Gastric Cancer Patients who have T3 (subserosal) or T4 (serosal) disease based on CT scan and intra-operative inspection with any N staging and M0 gastric cancer Patients planned for open or laparoscopic gastrectomy Patients undergoing gastrectomy with curative intent Lower age limit of research subjects 21 years old and upper age limit of 80 years old Ability to provide informed consent  Patients who undergo a palliative gastrectomy Patients who undergo a gastrectomy as emergency Vulnerable persons under age of 21 Patients receiving neoadjuvant therapy Patients presented with life-threatening bleeding from tumour ASA score of 4 & 5 Patients with another primary cancer within last 5 years Patients with gross peritoneal and liver metastasis at surgery
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Hypersplenism Liver Cirrhosis Hypersplenism  Patients with bad performance scale Patients with hepatic encephalopathy and tense ascites Patient with active esophageal variceal bleeding  Patients with hypocellular bone marrow (BM) Patients with renal failure
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Open Abdomen After Damage Control Laparotomy All admissions of trauma patients who sustain trauma necessitating damage control laparotomy Male and female patients 18 years or older  Children (<18 years old), prisoners, or pregnant patients Patients who have more than 1/3 loss of abdominal wall due to trauma Patients with baseline serum sodium of <120 mEq/L or >155 mEq/L
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Neoplasms Bone Neoplasms Be willing and able to provide written informed consent/assent for the trial Be 18 years of age on day of signing informed consent Have histologically or cytologically confirmed breast cancer. Oligometastatic lesions do not need to be biopsied but they must be strongly suspected to represent metastatic disease CT scan (Chest, Abdo + Pelvis), Whole Body Bone scan, and FDG-PET scan evidence of 1 to 5 metastases within 8 weeks of study registration Note: At least 1 of the 5 metastases must be deemed suitable for SABR treatment Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumour lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Participants for whom newly-obtained samples cannot be provided (e.g. inaccessible or participant safety concern) may submit an archived specimen only upon agreement from the study P.I's Have a performance status of 0-2 on the ECOG Performance Scale Demonstrate adequate organ function Life expectancy > 12 months Be willing and able to comply with all study requirements, including treatment, attending assessments and follow-up  Previous high dose radiotherapy (biological equivalent of 20 Gy in 5 fractions to the area to be treated) Evidence of visceral metastases in liver or brain Treatment with any chemotherapy agent within +/ weeks of SABR. Targeted therapy or endocrine therapy is permitted at any stage during the conduct of this study, however is not to be changed during the study period unless due to progression Evidence of Spinal Cord Compression Spinal Instability Neoplastic Score greater than or equal to 7 unless lesion reviewed by a neurosurgical service and considered stable Surgical fixation of lesion required for stability Lytic metastases in a long bone (femur or humerus) that which erodes the cortex Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Single once of doses are acceptable
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 0.25-0.5,  Hernia of Abdominal Wall Incisional Hernia animal model: New Zeeland female rabbits of 3000 gr of body weight -  any kind of illness in rabbit subjects
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Fetal Membranes, Premature Rupture singleton pregnancy with a definite history of current PPROM for the study group  Suspected fetal growth restriction (IUGR) Any gross fetal anomalies Abnormalities of placentation Uterine structural abnormalities Fetal jeopardy or intrauterine fetal death (IUFD) Women presenting with chorioamniointis with fever over 38 c abdominal tenderness, foul vaginal discharge and/or fetal tachycardia Diabetics, immunocompromized and cardiac patients Women with cervical cerclage Women with drained liquor
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Intracranial Aneurysm Subject ≥ 18 years old Subjects with non-ruptured or ruptured intracranial aneurysm that is referred for endovascular treatment Parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm Subject understands the nature of the procedure and provides voluntary written informed consent in accordance with the requirements of this study protocol Subject is willing to participate in the telephone follow-ups and to return to the investigational site for the post-procedure follow-up evaluations  Angiogram demonstrating that the aneurysm is not appropriate for endovascular treatment (i.e.: severe intracranial vessel tortuosity, stenosis, intracranial vasospasm not responsive to medical therapy) Mycotic or traumatic aneurysm Arteriovenous malformation (AVM) in the territory of the target aneurysm Two or more aneurysms (>2mm) in associated distribution Hunt and Hess Scale (HHS) of IV or V at for subject with ruptured aneurysms Life expectancy of less than 6 months as determined by the treating physician A planned staged procedure (i.e. a procedure where entire treatment with the devices (e.g. coils/stents) is completed over separate sessions) Previous neuro-interventional or neuro-surgical procedure of any kind within 30 days prior to the study procedure Intracranial mass (tumor, abscess, or other infection), or undergoing radiation therapy for carcinoma or sarcoma of the head or neck region Unsuitable for the antithrombotic and/or anticoagulant therapies
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Cystic Fibrosis Immunologic Deficiency Syndrome Turner Syndrome Congenital Hepatic Fibrosis Idiopathic Non-Cirrhotic Portal Hypertension Age 12 years or above, male or female Known diagnosis of NCPH, or to be at the risk for NCPH by virtue of underlying disease processes such as but not limited to; CGD, SCD, Mastocytosis, CVID, CF, and CHF seen at the NIH clinical center or via referral from outside institutions  Evidence of other forms of liver disease that typically result in cirrhosis Evidence of active chronic Hepatitis B infection as defined by the presence of hepatitis B surface antigen (HBsAg) in serum and elevated HBV DNA (> 10,000 IU/mL) Hepatitis C as defined by the presence of hepatitis C RNA in serum Primary sclerosing cholangitis as defined by liver histology Primary biliary cirrhosis as defined by cholestasis, +/ antimitochondrial antibody positivity and liver histology Wilson s disease as defined by ceruloplasmin below the limits of normal and liver histology and urinary copper consistent with Wilson disease Autoimmune hepatitis as defined by antinuclear antibody (ANA) of 3 EU or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy for autoimmune hepatitis Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy and homozygosity for C282Y. Patients with iron saturation indices of > 45% and serum ferritin levels of > 300 ng/ml for men and > 250 ng/ml for women will undergo genetic testing for hemochromatosis Bile duct obstruction as suggested by imaging studies done within the previous six months
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cancer Aged > 18 years old Capable of providing informed consent Histologically confirmed peritoneal carcinomatosis from appendiceal, colorectal, ovarian, or primary mesothelioma, with no systemic metastases Evidence of low-volume peritoneal disease defined by a PCI < 10 based on cross-sectional imaging / and / or diagnostic laparoscopy findings ECOG Eastern Cooperative Oncology Group (Zubrod) performance status of 0-2 Patients who are medically fit for surgery defined as the following No parenchymal hepatic metastases No evidence of clinical (jaundice), biochemical (abnormally elevated serum bilirubin and/or alkaline phosphatase) or radiological (ultrasound, CT, or MR) biliary obstruction No cross sectional imaging findings indicative of multi-segmental (>1 site) small bowel obstruction, or small bowel loops matted together, or gross disease of the small bowel mesentery characterized by distortion, thickening or loss of mesenteric vascular clarity  Peritoneal carcinomatosis index (PCI) > 10 Systemic (extraperitoneal) disease, pregnant, incarcerated Pregnant and lactating women. Women of reproductive age must be willing to use contraception during study therapy
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Immune Deficiency and Early BMF in Childhood Immune Deficiency and early BMF in childhood Common Variable Immunodeficiency (CVID) Genetic patients  Refusal to consent
Patient description: A 48-year-old white male with history of common variable immunodeficiency (CVID) with acute abdominal pain, fever, dehydration, HR of 132 bpm, BP 80/40. The physical examination is remarkable for tenderness and positive Murphy sign. Abdominal ultrasound shows hepatomegaly and abundant free intraperitoneal fluid. Exploratory laparotomy reveals a ruptured liver abscess, which is then surgically drained. After surgery, the patient is taken to the ICU.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Anal Fistulas ≥18 yrs old Perianal abscess (without spontaneous rupture) Abscess larger than 2 cm in diameter Signed informed consent  Malignancy within 5 yrs Previous radiotherapy of the abdomen and pelvis Recurrent abscess within 6 months Immune suppressed patients Pregnant and lactating women Abscess with horseshoe formation Allergy to Clindamycin
Patient description: A 6-month-old male infant has a urine output of less than 0.2 mL/kg/hr shortly after undergoing major surgery. On examination, he has generalized edema. His blood pressure is 115/80 mm Hg, his pulse is 141/min, and his respirations are 18/min. His blood urea nitrogen is 33 mg/dL, and his serum creatinine is 1.3 mg/dL. Initial urinalysis shows specific gravity of 1.017. Microscopic examination of the urine sample reveals 1 WBC per high-power field (HPF), 18 RBCs per HPF, and 5 granular casts per HPF. His fractional excretion of sodium is 3.3%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Glomerulonephritis Lupus Nephritis Systemic Lupus Erythematosus Patients must be 18 years of age or older and able to provide informed consent Patients must have at least 4 for SLE as defined by the American Rheumatism Association (ARA) Active glomerulonephritis with Renal biopsy within 1 year with class III or class IV active lupus nephritis, AND Abnormal urine analysis Greater than 10 RBC/hpf and cellular (RBC, WBC or mixed) casts, OR Greater than 10 RBC/hpf and proteinuria greater than 2 g/day, OR Proteinuria greater than 3.5 g/day No patients with severe proliferative lupus nephritis: a. very active renal histology with crescents or necrosis in more than 25% of glomeruli; or b. rapidly progressive glomerulonephritis (doubling of serum creatinine in less than or equal to 3 months); or c. severe impairment of renal function Cr greater than 2.5 mg/dL or GFR less than 50 mL/min measured by inulin clearance Patient has not had previous immunosuppressive therapy
Patient description: A 6-month-old male infant has a urine output of less than 0.2 mL/kg/hr shortly after undergoing major surgery. On examination, he has generalized edema. His blood pressure is 115/80 mm Hg, his pulse is 141/min, and his respirations are 18/min. His blood urea nitrogen is 33 mg/dL, and his serum creatinine is 1.3 mg/dL. Initial urinalysis shows specific gravity of 1.017. Microscopic examination of the urine sample reveals 1 WBC per high-power field (HPF), 18 RBCs per HPF, and 5 granular casts per HPF. His fractional excretion of sodium is 3.3%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acute Renal Failure ENTRY --Disease Characteristics-- Group 1: Patients on chronic hemodialysis Group 2: Patients at high risk of developing acute renal failure (ARF) after cadaveric renal transplantation Received high risk allograft Cadaveric kidneys with greater than 24 hours of cold ischemia time Donor had rising creatinine before organ procurement Donor over 60 years Group 3: Patients with ischemic ARF due to hypotension, surgery, or trauma ARF severity index 20-60% Creatinine clearance 12-14 mL/min Rising creatinine of at least 0.5 mg/dL per day for 2 days without evidence of recovery despite standard supportive care No drug or contrast induced renal failure No oliguric renal failure (creatinine clearance 3-4 mL/min) No prior chronic renal failure Baseline creatinine greater than 2.5 mg/dL (males) or 2.0 mg/dL (females) No ARF due to bacterial or fungal sepsis, nephrotoxins, acute tubulointerstitial nephritis, cyclosporine toxicity, bilateral renal vascular disease, or systemic diseases (hepatorenal syndrome, glomerulonephritis, renal vasculitis, etc.) --Prior/Concurrent Therapy-- Group 1: No recent immunosuppressive therapy Group 2 and 3: No prior renal transplantation No prior alpha-MSH Group 3: No prior dialysis for this episode of ARF No anticipated need for dialysis for at least 24 hours At least 12 hours since prior diuretics, mannitol, or dopamine At least 14 days since prior immunosuppressive drugs --Patient Characteristics-- No recent infection No known reaction to Terumo T175 dialyzer Not a prisoner Not pregnant or nursing No allergy to drugs used in study Not mentally impaired Group 3: No severe nonrenal medical condition that would interfere with the study (e.g., terminal cancer)
Patient description: A 6-month-old male infant has a urine output of less than 0.2 mL/kg/hr shortly after undergoing major surgery. On examination, he has generalized edema. His blood pressure is 115/80 mm Hg, his pulse is 141/min, and his respirations are 18/min. His blood urea nitrogen is 33 mg/dL, and his serum creatinine is 1.3 mg/dL. Initial urinalysis shows specific gravity of 1.017. Microscopic examination of the urine sample reveals 1 WBC per high-power field (HPF), 18 RBCs per HPF, and 5 granular casts per HPF. His fractional excretion of sodium is 3.3%.

Clinical trial eligibility criteria: eligible ages (years): 0.0-1.0,  Infant, Newborn, Diseases Pain ENTRY --Disease Characteristics-- Infants scheduled for surgery with postoperative inpatient care Must be born after 35 weeks or more gestational age No prenatal opiate exposure Part I patients Less than 12 months of age undergoing surgeries involving major thoracic, abdominal, or cardiac procedures No pneumonectomy, tracheal or bronchial stenosis reconstruction, diaphragmatic hernia repair, or surgeries resulting in high intraabdominal pressure (closure of large gastroschisis or omphalocele defects) No hepatic or renal transplantation Part II patients
Patient description: A 6-month-old male infant has a urine output of less than 0.2 mL/kg/hr shortly after undergoing major surgery. On examination, he has generalized edema. His blood pressure is 115/80 mm Hg, his pulse is 141/min, and his respirations are 18/min. His blood urea nitrogen is 33 mg/dL, and his serum creatinine is 1.3 mg/dL. Initial urinalysis shows specific gravity of 1.017. Microscopic examination of the urine sample reveals 1 WBC per high-power field (HPF), 18 RBCs per HPF, and 5 granular casts per HPF. His fractional excretion of sodium is 3.3%.

Clinical trial eligibility criteria: eligible ages (years): 13.0-60.0,  IGA Glomerulonephritis Histologically confirmed IgA nephropathy, diagnosed within the past 3 years Clinical presentation of either isolated hematuria/proteinuria for less than 3 years OR Acute nephritic or nephrotic syndrome No secondary forms of IgA nephropathy associated with chronic inflammatory disease of the bowel and liver No end stage renal failure as defined by the following: Glomerular filtration rate less than 15 mL/min AND Extensive glomerulosclerosis and tubulointerstitial damage No systemic lupus erythematosus or systemic (extrarenal) vasculitis (Henoch-Schonlein syndrome) Healthy volunteers will be accrued as a control group No other concurrent medical or psychiatric illness that would preclude study